Carey Colleen, Purohit Sharad, She Jin-Xiong
Medical College of Georgia, Center for Biotechnology and Genomic Medicine, 1120 15th St., Augusta, 30912, USA.
Expert Opin Med Diagn. 2010 Sep 1;4(5):397-410. doi: 10.1517/17530059.2010.508492.
Biomarkers are essential for the identification of high risk children as well as monitoring of prevention outcomes for type 1 diabetes (T1D). AREAS COVERED IN THIS REVIEW: This review discusses progress, opportunities and challenges in biomarker discovery and validation using high throughput genomic, transcriptomic and proteomic technologies. The authors also suggest potential solutions to deal with the current challenges. WHAT THE READER WILL GAIN: Readers will gain an overview of the current status on T1D biomarkers, an integrated review of three omic technologies, their applications and limitations for biomarker discovery and validation, and a critical discussion of the major issues encountered in biomarker development. TAKE HOME MESSAGE: Better biomarkers are still urgently needed for T1D prediction and prevention. The high throughput omic technologies offer great opportunities but also face significant challenges that have to be solved before their potential for biomarker development is fully realized.
生物标志物对于识别1型糖尿病(T1D)的高危儿童以及监测预防效果至关重要。
本综述讨论了使用高通量基因组、转录组和蛋白质组技术进行生物标志物发现和验证的进展、机遇和挑战。作者还提出了应对当前挑战的潜在解决方案。
读者将全面了解T1D生物标志物的现状,对三种组学技术及其在生物标志物发现和验证中的应用与局限性进行综合综述,并对生物标志物开发中遇到的主要问题进行批判性讨论。
对于T1D的预测和预防,仍然迫切需要更好的生物标志物。高通量组学技术提供了巨大机遇,但也面临重大挑战,在其生物标志物开发潜力得到充分实现之前,这些挑战必须得到解决。